Corporate digest
Add BT as a preferred sourceLonza Group
CHEMICALS and biotech company Lonza Group will buy a sterile drug product fill-and-finish facility in Stein, Switzerland, from Novartis. Lonza, which has a secondary listing on the Singapore Exchange, said it had entered into a binding contractual commitment for the acquisition, but did not disclose the purchase price.
It will use the facility to manufacture drug products for Novartis, as well as to provide production capacity for its additional customers.
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
That ‘cheap’ Malaysia condo could cost Singapore buyers far more than they think
These little-known SGX tech stocks are beating the market. What’s driving them up?
Indonesia equities plunge as MSCI removal triggers broad sell-off; tycoon-linked stocks hit hardest
